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Summary
Parkinson disease (PD) is caused by α-synuclein
misfolding in the substantia nigra par compacta cells of
the brain. A recent study (Willingham et. al., 2003)
demonstrated that over expression of wild type (WT) ∝-
synuclein in STP2 deletion (STP2Δ) S. cerevisiae strains
is toxic. Surprisingly, we did not observe any toxicity in
4741 (parent strain) and STP2Δ strains over expressing
WT ∝-synuclein or its mutant forms. Moreover, GFP
microscopy of α-synuclein in STP2Δ strains showed
phenotypes observed in strains with STP2. We observed
halos for strains over expressing WT ∝-synuclein and
the A53T mutant. ∝-synuclein was cytoplasmic for
strains with the A30P mutant and the A30P/A53T double
mutant. Western analysis demonstrated that neither the
levels of ∝ -synuclein expression nor the levels of
GAPDH, a pro-apoptotic protein changed in STP2Δ
strains. Furthermore, genetic deletion of GAPDH did not
show any enhanced growth in strains that
overexpressed ∝ -synuclein. The lack of ∝-synuclein
toxicity in STP2Δ in our study may be due to our use of
a different overexpression system, which did not yield
amounts high enough to overwhelm protein quality-
control systems and yield the toxicity that underlies PD
pathogenesis (Berke, 2003) of the cell.
Introduction
Described first by James Parkinson (1817), PD is one of the
most common neurodegenerative diseases in the world and
affects about 4 million people worldwide (Dauer, 2003).
Clinically, the major symptoms are tremor at rest, slowness
of movement (bradykinesia), reduced facial expressions, and
balance problems (Lang et. al., 1998). Pathologically, PD is
caused 1by the neurodegeneration of the substantia nigra
compacta (SNC), resulting in the loss of dopaminergic
neurons (Colcher A., 1999). The major clinical hallmark is
the presence of eosinophilic inclusions known as Lewy
Bodies (LBs) that forms an array of radiating fibrilar
structures (Spillantini et. al., 1998). Ultra structural analysis
had revealed that LBs are amyloid like fibrils consisting of
misfolded ∝-synuclein proteins (Spillantini et. al., 1998). One
can acquire PD by either inheriting the particular genetic
mutation or sporadically. In familial forms, the misfolding of
∝-synuclein is associated with the substitution of the 53rd
Threonine (Polymeropoulos et. al., 1997) and the 30th
Proline (Kruger, 1998) by an alanine.
The normal function of ∝-synuclein is still not well
known. But evidences do support their role in membrane
plasticity (Clayton et. al., 1998). The stabilization of its
secondary structure upon binding to synthetic membranes
(Davidson et al., 1998), the interaction of ∝-synuclein and
phospholipids (Perrin et. al., 2000), and the membrane
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binding characteristics of ∝-synuclein in cultured cells (Cole
et. al., 2002) suggests its role in the plasma membrane.
Most recent studies have discovered the lipid-binding
domain of ∝-synuclein and propose its roles in the regulation
of dopamine transporter activity (Wersinger et. al., 2003).
In 2003, Willingham et. al investigated the different
upstream and downstream factors linked with ∝-synuclein.
They showed 86 yeast genes that enhanced ∝ -synuclein
and huntingtin toxicity in their absence. Among them, one
was STP2. However, the study did not shed further light on
the connections between ∝-synuclein, huntingtin and STP2.
Structurally, STP2 or N-hydroxyarylamine sulfotransferase 2
belongs to the family of phenol preferring sulfrotransferases
(Khan et. al., 1995). Nevertheless, recent studies have
reported its role along with STP1 (AndAndreasson, 2002) as
a transcription factor for amino acid permease genes (de
Boer et. al., 2000) that transport extra-cellular amino acids to
the cell (Nielsen et. al., 2001). Most recent study by Eckert-
Boulet et. al., (2004) further expanded the role of STP2.
Transcriptional profiling of STP2/STP1 knockout strains of S.
cerevisiae using DNA micro array showed the up regulation
of several carbohydrate metabolic proteins such as
glyceraldehydes-3-phosphodehydrogenase (GAPDH3 or
Hsp35) and glucokinase (Eckert-Boulet et. al., 2004).
GAPDH3 is one among the three isoforms of
GAPDH protein, which is an enzyme that converts
glyceraldehyde-3-phosphate to 1,3-biphosphoglycerate in
the step 6 of glycolysis (McAlister, 1985). Recent studies
have revealed the diverse roles of GAPDH in the
neurodegeneration of dopaminerigc neurons (Fukuhara et.
al., 2001; Mazzola, 2002). Treating neurodegenerative cells
with known GAPDH inhibitors such as CGP 3466B
(Waldmeier, 2000), rasagiline (Maruyama, 2001), and
deprenyl & propargylamines (Tatton, 2003) have shown
rescuing effects. These evidences suggest that GAPDH may
play a role in the signal transduction pathways that control
neuronal apoptosis (Tatton (2), 2003). Among the three
isoforms of GAPDH, studies have also shown the link
between GAPDH3 or Hsp35 and protein misfolding during
stress (Delgado, 2003). A specific connection between ∝-
synuclein and GAPDH was shown by the demonstration of
the localization of GAPDH with the LBs of PD affected
patients (Tatton et. al., 2000).
Our study aims to investigate the connection
between ∝-synuclein and STP2. Based on the link between
STP2 and GAPDH (Eckert-Boulet et. al., 2004), we
hypothesize that the enhancement of ∝-synuclein toxicity in
STP2Δ  strains, as demonstrated by Willingham et. al.,
(2003) was due to elevated GAPDH levels. We examined
the toxicity of parent and STP2Δ strains over expressing WT
∝-synuclein. Furthermore, we extended the study by over
expressing the mutant forms of ∝ -synuclein too. To
investigate the role of GAPDH in the toxicity observed by
Willingham et. al., (2003), we examined the expression
levels of GAPDH in STP2Δ strains. Lastly, to investigate the
possibility of enhanced growth by GAPDH inhibition, we
examined GAPDHD over expressing WT ∝-synuclein and its
mutant forms.
Results
∝-Synuclein toxicity is not enhanced by STP2 Deletion
We first asked if WT ∝-synuclein toxicity was enhanced in
the absence of STP2. Surprisingly, the growth curves of
parent and STP2Δ strains over expressing WT ∝-synuclein
do not   demonstrate   any   toxicity   (Figure 1).  For further
confirmation, we conducted a yeast viability assay (serial
spotting) and still did not observe any toxicity as shown in
Fig. 2. We then repeated the experiments on parent and
STP2Δ strains over expressing the familial mutants of ∝-
synuclein-A30P & A53T, and an artificial double mutant
A30P/A53T. However, both assays (Fig. 1 & Fig. 2)
demonstrated the absence of any toxicity in any of the
STP2Δ strains. Our controls were strains with the parent
plasmid (pYES2) and GFP alone.
Figure 1. Growth Curves of parent and STP2D Strains
Yeast cells were grown in SC-URA/Galactose for α-Synuclein expression. Absorbance of the growing culture at 0hrs, 3hrs, 6hrs, 9hrs, 12hrs, 18hrs,
24hrs, and 36hrs were taken using the Hitachi U-200 spectrophotometer at 600nm. The growth curves of 4741(left, lines) and STP2D (right, dashed
lines) strains shows the absence of any toxicity. Both graphs were plotted to the same scale as demonstrated by the graph in the bottom.
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Figure 2. Serial Spotting of Parent and STP2D Strains
Yeast cells were grown to mid-log phase in SC-URA raffinose. They were then normalized to equal densities (2*107 cells/ml), serially diluted (five fold),
and spotted on SC-URA glucose (left) and galactose (right) plates. The assay indicates the absence of toxicity in both parent and STP2D strains over
expressing WT ∝-synuclein, A30P, A53T, and A30P/A53T. pYES2 and GFP alone were used as controls.
∝-Synuclein expression and size unchanged in STP2Δ
strains
To investigate the possibilities of ∝-synuclein aggregation
and differences in ∝-synuclein expression, we examined the
lystaes of parent and STP2Δ strains by Western analysis.
The immunoblotting shows no signal for the parent vector
pYES2 and the expected band of size 34 kDA for GFP alone
(Sharma, 2004). Equal amount of ∝-synuclein expression
was observed for the parent and STP2Δ  strains over
expressing WT ∝-synuclein and its mutant forms (Figure 3).
The minor differences between the different strains could be
accounted by the differences in the protein content as
demonstrated by coomassie staining (Figure 3). The
immunoblotting also did not show ∝-synuclein aggregates
(Figure 3), since the bands were of expected size with
~62kDA (Sharma, 2004). We also did not see any
differences in either expression level or in the size of ∝-
synuclein in strains over expressing the mutant forms of ∝-
synuclein (Figure 3).
Cytoplasmic and peripheral localization of ∝-synuclein
unvaried in STP2Δ
GFP microscopy was conducted at the 24th hour after
induction on all the parent and STP2Δ strains to examine the
phenotypes of ∝-synuclein expression (Rows 1 & 2; Figure
4). Strains with the parent plasmid and GFP alone were
used as controls (Columns 1 & 2; Figure 4). To evaluate
phenotypic changes with time, we examined the strains at
the  48 th hour also ( Rows 2, 3, 5 & 6;  Figure 4 ).  Extensive
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Figure 3. Western Analysis of Parent and STP2D Lysates
Yeast cells (2.5x107 cells/ml) were washed in 50mM Tris (pH 7.5),
10mM Nan3 and solubilized in Electrophoresis Sample Buffer (ESB;
Burke, 2000). Samples (25 ul) were run on pre-cast 10-20% Tris-
Glycine SDS gels (Invitrogen), using See Blue (15 ul) as the
molecular standard (Invitrogen).  Gels were transferred to PVDF
membranes (BioExpress) and probed with the antibodies: anti-α-
synuclein (Santa Cruz, Biotech). To detect the antibodies, the blot
was treated with color development solution. WT ∝-synuclein, A30P,
A53T, and A30P/A53T migrated to 62 KDA and GFP alone untill 34
KDA. The blot shows the absence of difference in neither size or
expression levels of ∝-synuclein.
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Figure 4. GFP Analysis of Parent and STP2D Strains
To analyze cells under fluorescent microscopy, expression was induced for 24 hours and was diluted to a density of 5*106 cells/ml in 25ml of SC-
URA/Galactose media. Cells weregrwon to log-phase, and resuspended in 250ul of SC-URA/Glucose media to concentrate them 100-fold. The figure
shows intense cytoplasmic localization for all the strains with A30P mutant and the double mutant A30P/A53T and bright halos for all the strains with
WT ∝-synuclein and the A53T mutant. No phenotypic difference was observed at 48hrs after induction.
cytoplasmic localization of ∝-synuclein was observed in the
parent and STP2Δ strains over expressing GFP alone, WT
∝-synuclein and the A30P mutant (Columns 2, 3, and 4;
Figure 4). However, halos could be seen for strains over
expressing A53T and A30P/A53T suggesting the localization
of ∝-synuclein in the plasma membrane (Columns 5 and 6;
Figure 4). Among the different phenotypes we investigated,
intense cytoplasmic localization of ∝-synuclein in the form of
spherical bodies also known as foci was seen in the strains
over expressing the WT ∝-synuclein and the A53T mutant
(Figure 5; top). Quantification of cells with foci at the 24th and
48th hours shows that the % of foci decreases for the parent
strain over expressing WT ∝-synuclein and increased for the
A53T mutant (Figure 5; bottom). An increase in the % of foci
was also seen in the STP2Δ strains overexpressing WT ∝-
synuclein and the A53T mutant (Figure 5; bottom).
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Figure 5. GFP Analysis Reveals Foci. The cells were prepared as in Fig. 4. Foci was  observed in in all the 
strains overexpressing WT and A53T ? -synuclein. Quantification was carried out by counting cells in t he 
number of foci in six adjacent fields. The number of foci decrea sed for parent strain with WT ? -synuclein at 
the 48th hour, but increased for the STP2 ? strains with WT ? -synuclein and A53T mutant (bottom). An 
increase in the % of foci was also seen in the parent strain wit h the A53T mutant (bottom).
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Figure 5. GFP Analysis Reveals Foci
The cells were prepared as in Fig. 4. Foci were observed in in all the
strains overexpressing WT and A53T ∝-synuclein. Quantification was
carried out by counting cells in the number of foci in six adjacent
fields. The number of foci decreased for parent strain with WT ∝-
synuclein at the 48th hour, but increased for the STP2D strains with
WT ∝-synuclein and A53T mutant (bottom). An increase in the % of
foci was also seen in the parent strain with the A53T mutant (bottom).
GAPDH Levels Remains Unchanged in STP2Δ strains
We hypothesized that the enhanced toxicity observed by
Willingham et. al., (2003) was due to elevated levels of
GAPDH. To test this hypothesis, we investigated the
expression levels of GAPDH by Western analysis on the cell
lysates of parent and STP2Δ strains over expressing WT ∝-
synuclein (Figure 6). The immunoblotting shows the GAPDH
band with expected size of 43.5Kda. However, we observed
the absence of any difference in GAPDH expression
between the parent and STP2Δ strains. We also did not see
any difference between the parent and STP2Δ strains over
expressing the mutant forms of ∝-synuclein--A30P & A53T
and the A30P/A53T. The cell lysates of strain with the parent
plasmid and GFP alone were used as controls.
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Figure 6. Western Analysis of Parent and STP2 ? Lysates Examining GAPDH Expression.
TheWestern was conducted as described in Fig. 3. The blot was probed with the primary anti - GAPDH 
antibody (ChemiCon International) followed by the secondary anti -PGK (Molecular Probes) antibody. 
As expected, the GAPDH protein migrated till 43.5 KDA.The blot shows the absence of difference in 
GAPDH expression between Parent and STP2? strains.
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Figure 6. Western Analysis of Parent and STP2D Lysates
Examining GAPDH Expression
The Western was conducted as described in Figure 3. The blot was
probed with the primary anti- GAPDH antibody (ChemiCon
Inter ational) followed by the secondary anti-PGK (Molecular Probes)
antibody. As expected, the GAPDH protein migrated till 43.5 KDA.
The blot shows the absence of difference in GAPDH expression
b tween Parent and STP2D strains.
Deletion of GAPDH does not enhance growth
Although we did not observe any toxicity in STP2Δ strains,
we asked whether the deletion of GAPDH might enhance
growth in a STP2 independent manner. To investigate this
possibility, we used a strain lacking GAPDH3. We compared
the growth of parent and GAPDHΔ strains over expressing
WT ∝ -synuclein and it mutant forms by serial spotting
(Figure 7). Further extending the study with GAPDHD over
expressing A30P, A53T, and A30P/A53T also did not shown
any enhancement in growth. The strains with the parent
plasmid and GFP alone were again used as controls (Figure
7).
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Figure 7. Serial Spotting of Parent and GAPDHD Strains
The spotting was conducted as described in Figure. 2. The assay
indicates the absence of any toxicity in both parent and GAPDHD
strainsover expressing WT ∝ -synuclein, A30P, A53T, and
A30P/A53T. pYES 2and GFP alone were used as controls.
Discussion
In this study, we investigated the enhanced ∝-synuclein
toxicity observed by Willingham et. al., (2003) in STP2
deletion strains of S. cerevisiae and extended this analysis
to familial mutants. We proposed this enhanced toxicity was
due to increased GAPDH levels. However, we neither
observed toxicity nor difference in GAPDH levels in STP2Δ
strains.
STP2 toxicity may require higher expression of _-
synuclein
Our study demonstrated the absence of toxicity in STP2Δ
strains through OD600 and spotting assays. This is
paradoxical to the results of Willingham et. al., (2003).
Besides, we did not see toxicity in the parent strain too. This
is also contradictory. Because, other recent studies in yeast
(Outeiro et. al., 2003) and other model systems such as
mice have demonstrated over expression of ∝-synuclein to
be toxic (Yamada, 2004). The absence of the toxicity should
not be because of the strains; since both Willingham et. al.,
(2003)  and us used the 4741 based STP2 deletions and
galactose based ∝-synuclein induction systems. However,
the vectors used by Willingham et. al., (2003) was p426,
where as we used the pYES2 vector, which posses minor
differences in the sequence. This might affect the galactose
based induction system to such an extent that the optimal
amount of ∝-synuclein necessary for being toxic in STP2Δ
background may not be expressed. Optimal amount of
misfolded proteins is a crucial factor for toxicity or aggregate
formation (Outerio et. al., 2003).  Because, if the optimal
amount of ∝-synuclein is not present, the protein quality-
control system of cells, including uniquitin ligase (Kitada,
1998), Hsp 70 (Hartl, 2002), and uniquitin C-terminal
hydrolase (Leroy, 1998; Liu, 2002) may cope up with
misfolded ∝-synuclein (Berke, 2003; Taylor, 2002). To
investigate the effect of mutant ∝ -synuclein in inducing
toxicity, we extended the study by over expressing the
mutant variants of ∝-synuclein--A30P & A53T, and the
artificial double mutant A30P/A53T. Similar to the over
expression of WT ∝-synuclein, the mutant forms are also
shown to be lethal (Outerio et. al., 2003). However, we did
not see any difference in the growth rate of the parent and
STP2Δ  strains. This might also be accounted by the
difference in the vector system we used for over expressing
∝-synuclein.
STP2 does not appear to influence in vivo and in vitro a-
synuclein aggregation
We next examined the presence of any abnormal
phenotypes in parent and STP2Δ  strains by GFP
microscopy. Between the two types, we did not see any
difference in the phenotypes (Fig. 4) thereby showing the
neutral effect of STP2 deletion. Previous studies have shown
that ∝-synuclein is a plasma membrane specific protein
(Wersinger et. al., 2003). The parent and STP2Δ strains over
expressing WT ∝-synuclein and it mutant form A53T showed
halos suggesting the localization of ∝-synuclein in the
plasma membrane. This indicates that the A53T mutation is
neutral to the plasma binding of ∝ -synuclein. The
cytoplasmic localization of ∝ -synuclein in the plasma
membrane for parent and STP2Δ  strains with the A30P
mutant and the double mutant A30P/A53T suggests the
necessity of the 30th proline for plasma membrane binding.
Our results agree with other studies that have conducted
similar experiments (Outerio et. al., 2003; Wang et. al.,
2004). Evaluation of any variation in the dominant phenotype
at the 48th hour did not demonstrate any phenotypic
differences. This suggests the absence of the progress of
any lethal or unusually phenotypes that are undetectable at
the 24th hour.
Although the dominant phenotypes were plasma
membrane and cytoplasmic localization, we also observed
foci in the cytoplasam of parent and STP2Δ strains over
expressing WT, and A53T. However, the percentage of foci
was very low. This further indicates the absence of the
optimal amount of ∝-synuclein required for being toxic, if foci
are the cause of toxicity in the study by Willingham et. al.,
(2003). Because, simply doubling the amount of ∝-synuclein
is shown to change the membrane localization of ∝ -
synuclein to cytoplasmic foci (Outerio et. al., 2003).
Quantification of this at the 24th and 48th hours showed a
decrease in the number of foci for parent strain with WT ∝-
synuclein and an increase for STP2Δ with WT ∝-synuclein
and A53T mutant. An increase in foci was also seen for
parent strain with A53T mutant. The question of whether the
foci are aggregates of ∝-synuclein remains to be answered.
However, the absence of toxicity highlights the hypothesis of
the ‘Protective Function of Aggregates’ (Goldberg, 2000).
Whether the foci are ∝ -synuclein aggregates or not, the
decrease in foci for parent strain with WT suggests the
activation of chaperone systems that removes them (Hartl,
2002). However, a definitive pattern cannot be formulated,
since the number of foci is increasing for STP2Δ with WT ∝-
synuclein and its mutant form A53T and also for parent
strain with A53T mutant. To make further conclusions, the
experiment needs to be repeated. But it suggests the
existence of a molecular overlap in the signal transduction
pathways of the three types of strains that shown an
increase in foci formation at the 48th hour.
Although, aggregation is not a prerequisite for ∝-
synuclein toxicity (Goldberg, 2000), it is possible that the
toxicity demonstrated by Willingham et. al., (2003) was due
to ∝ -synuclein aggregation. Besides, in vitro studies by
Conway et. al., (1998) have shown that ∝ -synuclein
mutations A30P and A53T accelerate the oligomerization of
∝-synuclein. Recent studies on yeast have also shown
difference in the expression levels of ∝-synuclein with A30P
mutant having elevated expression over WT and A53T
(Outerio et. al., 2003). We investigated aggregate formation
by immunoblotting for ∝-synuclein on the cells lysates
prepared from parent and STP2Δ strains. However, we did
not see any difference on the size and on the expression
level of ∝ -synuclein. The absence of aggregates or
multimers might also be because of the absence of
adequate amount of ∝-synuclein necessary for fibrilization
due to the induction system we used.
Relevance of GAPDH
Based on Eckert-Boulet et. al., (2004), we proposed that the
enhanced toxicity in STP2Δ (Willingham et. al., 2003) was
due to GAPDH over expression. However, immunoblotting
demonstrates the absence of any difference in the
expression level of GAPDH between the parent and STP2Δ
strains. The absence of the difference might be because of
the difference in the strains used. Eckert-Boulet et. al.,
(2004) used the yeast strain gap/ura3 M4054, where as we
used 4741. Or else it might be because of the high signal-to-
noise ratio of the DNA Micro array system used by Eckert-
Boulet et al., (2004) leading to a false positive signal for
GAPDH.
 Our initial hypothesis was the role of GAPDH in
STP2 dependent ∝-synuclein toxicity was demonstrated to
be invalid. Therefore, we proposed that deletion of GAPDH3
might enhance the growth in both parent and STP2D strains,
if ∝-synuclein toxicity is independent of STP2 yet dependent
on GAPDH. Similar studies in mice had resulted in the
rescue of dopaminergic neurons undergoing apoptosis
(Fukuhara et. al., 2001). However, we did not demonstrate
any enhanced growth in both parent and GAPDHΔ strains.
This could be explained by the fact that there might not have
been any toxicity in the first place because of the absence of
optimal amount of ∝-synuclein necessary for being toxic. Or
else, GAPDH might not have any link between apoptosis or
∝-synuclein in S. cerevisiae.
Conclusion
We conclude that the absence of enhanced STP2
dependent ∝-synuclein toxicity in our study was due to the
difference in the vector used. Our results propose a model
where the pYES2 based induction systems expresses ∝-
synuclein below the optimal amount that is required to
bypass  the  protein  quality -controlled  systems  of  the  cell
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Figure 8. Molecular Model that Links STP2, ∝-synuclein and GAPDH
We predict that the absence of STP2 dependent ∝-synuclein toxicity as shown by Willingham et. al., (2003) in our study was due to the difference in
the vector system used. In our system (4741/pYES2), ∝-synuclein expression was not adequate enough toby pass the protein quality-control systems
in the cell. Also, the GAPDH expression levels did not change in our STP2D strains, which was paradoxiacal to the observation of Eckert-Boulet et. al.,
(2004). We assume this difference was because of the difference in the yeast strain used.
(Figure 8). Therefore, to completely verify the role of GAPDH
in STP2 dependent ∝-synuclein toxicity, the study needs to
be repeated with other vectors.
Experimental Procedures
α-Synuclein Constructs
Human wild type and A53T mutant α-synuclein cDNAs were a gift
from Christopher Ross (Johns Hopkins University).  A30P and
A30P/A53T mutant α-synuclein were created from wild type and
A53T mutant α -synuclein, respectively, using site-directed
mutagenesis (Invitrogen).  Wild type and mutant α-synuclein cDNAs
were sub cloned into the pYES2.1/V5-His- TOPO yeast expression
vector (Invitrogen).  All α-synuclein forms were also tagged with GFP
using a two-step cloning strategy.  α-Synuclein cDNAs were first sub
cloned into mammalian expression vectors, pcDNA3.1/C-terminal
GFP and pcDNA3.1/N-terminal GFP (Invitrogen).  α-Synuclein-GFP-
CT fusion genes were then amplified and subcloned into yeast
expression vector, pYES2.1.  Chemically competent E. coli were
transformed with the α-synuclein and α-synuclein-GFP expression
plasmids and grown on LB-ampicillin media for selection.  All
constructs were verified by DNA sequencing.  The parent pYES2.1
vector (Invitrogen) and GFP in pYES2.1 vector were used as
controls.
Expression in Yeast Strains
α-Synuclein expression plasmids were transformed as described
(Burke, 2000) into URA-3-deficient, STP2-deficient, and GAPDH3-
deficient S. cerevisiae strains 4741, 6603, and 4422 respectively. For
selection, yeast cells were grown on synthetic-complete media
lacking uracil (SC-URA).  Presence of α-synuclein constructs was
confirmed by polymerase-chain reaction.  The pYES2.1 vector,
containing a galactose inducible promoter (GAL1), allowed for
regulated α-synuclein expression.  Yeast cells were first grown
overnight in SC-URA glucose (2%) media at 30°C.  Cells were
washed with water and diluted to log-phase in SC-URA galactose
(2%) media to induce expression.
Western Analyses
Yeast cells (2.5x107 cells/ml) were washed in 50mM Tris (pH 7.5),
10mM Nan3 and solubilized in Electrophoresis Sample Buffer (ESB;
Burke, 2000) containing 2% SDS, 80mMTris (ph 6.8), 10% glycerol,
1.5% DTT, 1mg/ml bromophenol blue, and a cocktail of protease
inhibitors and solubilizing agents (1% Triton-X 100, 1mM PMSF, 1mM
benzamidine, 1mM sodium orthovanadate, 0.7 µg/ml pepstatin A, 0.5
µg/ml leupeptin, 10µg/ml E64, 2µg/ml aprotinin, and 2µg/ml
chymostatin). Samples (20-30 ul) were run on pre-cast 10-20% Tris-
Glycine SDS gels (Invitrogen), using See Blue (15 ul) as the
molecular standard (Invitrogen).  Gels were transferred to PVDF
membranes (BioExpress) for 120 minutes at 30V and probed with the
antibodies: anti-α-synuclein (Santa Cruz, Biotech), anti- GAPDH
antibody (ChemiCon International) and anti-PGK (Molecular Probes);
secondary antibody for anti-GAPDH antibody. Antibodies were diluted
in blocking buffer as recommended. To detect the antibodies, the
following color development solution was used: 100ml Tris Buffer (pH
9.5) containing 15mg/ml BCIP and 30mg/ml of NBT dissolved in
100% and 70% dimethylformamide, respectively (BioRad).
Table 1. Different α-synuclein Constructs and the Respective
Strains Used
Construct Strain S. cerevisiae Strain
Used
pYES2 Parent 4741
GFP (CT) Parent 4741
WT-α-synuclein-GFP (CT) Parent 4741
A30P α-synuclein-GFP (CT) Parent 4741
A53T α-synuclein-GFP (CT) Parent 4741
A30P/A53T α-synuclein-GFP (CT) Parent 4741
pYES2 STP2Δ 6603
GFP (CT) STP2Δ 6603
WT-α-synuclein-GFP (CT) STP2Δ 6603
A30P α-synuclein-GFP (CT) STP2Δ 6603
A53T α-synuclein-GFP (CT) STP2Δ 6603
A30P/A53T α-synuclein-GFP (CT) STP2Δ 6603
pYES2 GAPDHΔ 4422
GFP (CT) GAPDHΔ 4422
WT-α-synuclein-GFP (CT) GAPDHΔ 4422
A30P α-synuclein-GFP (CT) GAPDHΔ 4422
A53T α-synuclein-GFP (CT) GAPDHΔ 4422
A30P/A53T α-synuclein-GFP (CT) GAPDHΔ 4422
Growth Analyses
For OD600 analysis, yeast cells were grown overnight in SC-
URA/Glucose and were washed the next day twice with water and
transferred into two sets of cultures (SC-URA/Glucose and SC-
URA/Galactose) at early log-phase (5*106 cell/ml). The absorbance
readings of yeast cells expressing α-synuclein at 0hrs, 3hrs, 6hrs,
9hrs, 12hrs, 18hrs, 24hrs, and 36hrs were taken at 600nm using the
Hitachi U-200 spectrophotometer.  For spotting, yeast cells were
grown to mid-log phase in SC-URA raffinose (2%), normalized to
equal densities (2*107 cells/ml), serially diluted (five-fold), and
spotted on SC-URA glucose (2%) or galactose (2%) plates.
Photographs were scanned after 2-3 days of growth.
GFP Microscopy and Quantification
To analyze cells under fluorescent microscopy, expression was
induced for 24 hours as described previously and was diluted to a
density of 5*106 cells/ml in 25ml of SC-URA/Galactose media and
allowed to grow into log phase. Cells were then washed twice with
deionized water and resuspended in 250ul of SC-URA/Glucose
media to concentrate them 100-fold. 10 ul of the cells was added to a
slide and viewed under the Zeiss Axiovert-100 fluorescent
microscope and images were acquired under blue-filter settings using
the Metamorph 4.0 imaging software.  Quantification was carried out
by counting cells in the number of each type of phenotype in six
adjacent fields and calculating the ratio of cells displaying certain
patterns: general fluorescence (cytoplasmic localization), bright halos
(peripheral localization), and foci (possible aggregation) to the total
number of cells in the six fields together.
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